Get started

Buying

Risky Insider Buy Signal Trade on LFMDOur insider based AI generated a significant buy signal for LFMD yesterday. It could be an interesting but high risky trade setup. Technically it seems to be the potential end of an elliott wave two correction, after classical ABC correction. So next level would be around $24.52. In bad case, the stock will fall again after touching the yellow resistance. In that case we might stop the position early. Nevertheless, it's a high risky small cap stock, with an risk/reward ratio of 7.59, which is great. We put a very small position into (0.5% of portfolio value).
NASDAQ:LFMDLong
by director_scope
ET Insider Buy Signal & Technical BullishAnother interesting signal from the oil sector was generated yesterday by our directorscope AI system. With a risk / reward ratio of 5.3 over the medium term, this could be a good trade. Elliott Wave Analysis: The stock could be inside a wave 3. And within the wave in an intermediate correction. With current impulses from the oil price, the interim correction could now be over. RSI shows at this points divergence behavior, which is bullish in short term as well. Stochastic indicator shows neutral levels. We set a small position (0.5% of the portfolio value) with a very tight stop. Keep in mind, this stock is highly depending on oil prices.
NYSE:ETLong
by director_scope
MTDR Insider Buy Signal & Technical BullishOur directorscope AI system generated yesterday a significant buy signal for MTDR. Todays technical analysis shows, that this could be an interesting trade opportunity with a risk/reward ratio of 4. Elliott Wave Analysis: The stock is inside a wave 4. Fibonacci Analysis shows, that the typical correction level is reached and the final wave 5 could start now. RSI shows at this points divergence behavior, which is bullish in short term as well. Stochastic indicator shows oversold levels. We will open the trade for ourselves with a small position and risk 1% of the portfolio value. Keep in mind, this stock is highly depending on oil prices.
NYSE:MTDRLong
by director_scope
EUR/USD TOWARDS POSSIBLE REVERSAL !! TIME FOR LONG !!EUR/USD Is Certainly Near The Reversal Which Means That Eur/Usd will Possibly Rise therefore its a BUYING/LONG OPPORTUNITY. The reversal often takes a few legs before occurring therefore a strict Stop Loss level is suggested as well. Find the Buying zone, Stop Loss and Targets below! Note: This is for education purpose only. Do your own research before any action! Buying-Zone : 1.18250-1.18300 Stop Loss: 1.17920 1st Target: 1.20730 2nd Target: Will be discussed on updated part
Long
by M_Shariq
$CLF averaging up once again*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My teams original entry for $CLF is at $13. We averaged up on 5/23/21 at $18.06. On 6/10/21 we hit our take profit 1 at $24 per share and secured most of our profits. My team averaged up once again on our remaining positions yesterday before the market closed at $20.60 per share. My team still plans to close this trade completely once our trade reaches our take profit 2. Investors still looking for positions should be advised that $CLF may retest our red trendline before this occurs...but current shareholders have no reason to be concerned with this scenario for it will offer additional buying opportunities. If you want to see more, please like and follow us @SimplyShowMeTheMoney
NYSE:CLFLong
by SimplyShowMeTheMoney
Progenity (PROG) situationProgenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products as well as innovating in the field of precision medicine. Revenue source is from Innatal, Preparent, and pathology molecular testing. Recently announced $40 Million Private Placement (8-k) Launches strategic transformation by eliminating costs of Progenity Genetics Lab and focusing on robust, innovative R&D pipeline. With focuses on: --> Cost-Focus --> New opportunities and innovation --> Continued development of GI-targeted therapeutics and oral biopharmaceuticals delivery system (OBDS) A variety of "Analysts" state that PROG is either a buy or hold as they expect increases in revenue and EPS Insider (Athyrium) buying since the 3rd around $47 millions dollars A new fraud case has been opened against Officers and Directors of Progenity for over billing the US government by 10.3 million dollars
P
by Mikey_Scali
2